Long-term neuroprotective efficacy of VEMSA-PD nasal drops: An innovative approach for management and mitigation of Parkinson’s disease symptoms

Background and Purpose: Parkinson's Disease (PD) is a neurodegenerative disorder primarily affecting dopamine-producing neurons in the brain, leading to a spectrum of motor and non-motor symptoms.Methods: This study introduces VEMSA-PD nasal drops as a potential candidate, which, based on our investigations, has shown promising neuroprotective properties.VEMSA-PD nasal drops are a proprietary herbal compound enriched with micro-emulsions and bioactive components that are beneficial for the Central Nervous System (CNS) and managing PD.Our experimental model initially involved inducing PD in mice using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, administered at a dosage of 20 mg/kg (i.p) twice daily for five days.Result: Subsequent treatment with VEMSA-PD nasal drops revealed a significant neuroprotective effect.Notably, co-administration of MPTP with VEMSA-PD (2 drops, 3 times/day) almost restored the striatum's glutathione (GSH) levels and antioxidant enzyme activity to normal levels in the MPTP-induced group (1.33 ± 0.06).Additionally, the elevated malondialdehyde (MDA) levels seen in the MPTPinduced group (8.11 ± 0.05) were considerably reduced in the group treated with VEMSA-PD, achieving MDA levels of 2.63 ± 0.143 in the striatum and 4.45 ± 0.169 in the treated group.Conclusion: Human PD patients received VEMSA-PD nasal drops for six months in the research.Uric acid levels decreased significantly pre-, fourmonth-, and post-treatment, suggesting VEMSA-PD may manage PD-related metabolic dysregulation.In conclusion, VEMSA-PD nasal drops reduce uric acid levels in human PD patients and protect neurons in animal models of PD.